Schering-Plough submits response to FDA for Saphris
Thursday, February 26, 2009 13:00 IST Kenilworth, New Jersey
Schering-Plough Corporation has responded to the US Food and Drug Administration (FDA) complete response letter for Saphris (asenapine) sublingual tablets, which was received in January 2009.